Last updated on October 2018

A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)


Brief description of study

This is a phase 1 study (the first stage in testing a new treatment to see how safe and tolerable the treatment is) which will include patients with acute myeloid leukemia (AML) that has either returned or has a more than a 70% chance of coming back and cannot have a bone marrow transplant.

This study will see whether modifying a patient's AML cells to produce IL-12 and giving it back to the patient is safe and useful in patients with AML that cannot have bone marrow transplants.

Clinical Study Identifier: NCT02483312

Contact Investigators or Research Sites near you

Start Over

Mark Minden, M.D.

Princess Margaret Centre Centre
Toronto, ON Canada
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.